On January 28, 2026, scientists may have uncovered a brand-new pathogenic mechanism of asthma, a discovery that holds the potential to revolutionize the treatment protocols for this condition.

Researchers from Case Western Reserve University in Cleveland, Ohio, USA, have announced the identification of a previously unknown class of molecules that may play a pivotal role in the inflammatory responses associated with asthma.

The study results indicate that these chemical substances, named leukotriene mimics, may be far more significant than the leukotrienes that have been the primary focus of medical research for decades.

"We have discovered a class of structurally similar molecules that are produced in the human body via entirely distinct chemical pathways," stated Dr. Robert Salomon, the study's lead investigator and a professor of chemical research, in a press release. "We have named these molecules leukotriene mimics and believe they are the dominant drivers of the disease-causing inflammatory cascade."

Funded by the National Institutes of Health (NIH) of the United States, the findings were published in the January issue of the Journal of Allergy and Clinical Immunology.

For many years, the scientific community has held the belief that inflammation triggered by asthma is primarily driven by leukotrienes—chemical molecules released by white blood cells when the airways are stimulated.

The development of numerous asthma therapeutic drugs has centered on blocking the actions of leukotrienes. However, the research by Dr. Salomon's team reveals that leukotriene mimics are generated through a fundamentally different mechanism. Unlike leukotrienes, which are synthesized via enzymatic catalysis, leukotriene mimics are formed when free radicals add oxygen atoms to lipids—fatty or waxy compounds synthesized by the human body. Free radicals are highly reactive molecules that can cause damage to the body if left unregulated.

Dr. Salomon described the process: "The reaction initiated by free radicals is like an explosion or a fire. Much like oxygen reacting with fuel to produce a flame, this process can easily spiral out of control."

The researchers hypothesize that individuals with asthma may have lower levels of enzymes and antioxidants that normally suppress free radicals and prevent them from causing cellular damage.

Leukotrienes and leukotriene mimics act like keys that turn an ignition switch to start an engine; both activate the same receptor to trigger an inflammatory response, which ultimately leads to airway constriction and breathing difficulties.

Current asthma medications, including Singulair, exert their therapeutic effects precisely by blocking this receptor.

Nevertheless, the researchers suggest that future treatment strategies may directly target the free radical reaction process itself.

"The true significance of this discovery lies in the potential to develop medications that inhibit or regulate the free radical reaction process to treat this condition, rather than relying solely on receptor-blocking drugs," Dr. Salomon noted.

Inflammatory responses are not always harmful; they assist the body in repairing damaged tissue and also play a role in the normal physiological functions of the brain. Overly broad inhibition of inflammatory responses may interfere with these beneficial biological processes.

Dr. Salomon further explained: "If the molecules causing the problem are leukotriene mimics rather than leukotrienes, then the optimal therapeutic approach would be to prevent the formation of these molecules, rather than simply blocking the 'ignition switch'."

To validate this theory, the research team conducted a comparative analysis of urine samples from patients with mild and severe asthma, alongside samples from healthy individuals.

The results demonstrated that the levels of leukotriene mimics in patients with asthma were four to five times higher than those in healthy subjects.

Furthermore, leukotriene mimic levels were highly correlated with the severity of asthma, suggesting that these molecules may in the future assist physicians in monitoring asthma progression or evaluating the efficacy of treatment regimens.

Moving forward, the researchers plan to further investigate whether leukotriene mimics are also involved in the pathogenesis of other respiratory diseases, such as respiratory syncytial virus (RSV) infection, bronchiolitis in infants and young children, and chronic obstructive pulmonary disease (COPD).